Novo Nordisk shares slide after semaglutide Alzheimer's trial misses primary goalProactive Investors • 11/24/25
Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?Zacks Investment Research • 11/24/25
Holiday air travel, Novo Nordisk trial results, 'Wicked: For Good' debut and more in Morning SquawkCNBC • 11/24/25
Novo Nordisk, Waldencast And Other Big Stocks Moving Lower In Monday's Pre-Market SessionBenzinga • 11/24/25
Novo Nordisk shares plunge as oral semaglutide Alzheimer's trial fails to show clinical benefitInvezz • 11/24/25
Novo Nordisk shares fell sharply after it said a pill with the key ingredient in Ozempic and Wegovy didn't slow Alzheimer's disease in two late-stage clinical trialsWSJ • 11/24/25
Novo Nordisk's oral GLP-1 drug didn't work on Alzheimer's as hoped, and the stock tumblesMarket Watch • 11/24/25
Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's in Trials. Biogen Jumps.Barrons • 11/24/25
Novo Nordisk Dives As Ozempic Fails To Slow Alzheimer's; Lilly Falls, Biogen JumpsInvestors Business Daily • 11/24/25
Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progressionGlobeNewsWire • 11/24/25
Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant?The Motley Fool • 11/23/25
2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026?The Motley Fool • 11/22/25